- Home
- SIBN
SIBN
SI-BONE Inc.
as 06-20-2025 4:00pm EST
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SANTA CLARA |
| Market Cap: | 805.4M | IPO Year: | 2018 |
| Target Price: | $24.40 | AVG Volume (30 days): | 451.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.63 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.70 - $20.05 | Next Earning Date: | 08-04-2025 |
| Revenue: | $176,601,000 | Revenue Growth: | 22.60% |
| Revenue Growth (this year): | 19.48% | Revenue Growth (next year): | 16.86% |
Stock Insider Trading Activity of SI-BONE Inc. (SIBN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| DUNN JEFFREY W | SIBN | Director | Jun 5 '25 | Sell | $19.05 | 3,377 | $64,334.89 | 17,354 | |
| RECUPERO ANTHONY J | SIBN | President, Commercial Ops | May 16 '25 | Sell | $19.67 | 4,147 | $81,109.29 | 282,370 | |
| Maheshwari Anshul | SIBN | Chief Financial Officer | May 16 '25 | Sell | $19.67 | 12,009 | $236,611.68 | 224,507 | |
| FRANCIS LAURA | SIBN | Chief Executive Officer | May 16 '25 | Sell | $19.74 | 17,797 | $349,134.00 | 500,698 | |
| Pisetsky Michael A | SIBN | SVP, Ops & Adm/Chief Legal Ofr | May 16 '25 | Sell | $19.51 | 3,459 | $68,005.57 | 264,636 | |
| Maheshwari Anshul | SIBN | Chief Financial Officer | May 12 '25 | Sell | $19.02 | 4,937 | $93,925.93 | 224,507 | |
| Maheshwari Anshul | SIBN | Chief Financial Officer | May 7 '25 | Sell | $17.59 | 33,287 | $599,033.35 | 224,507 | |
| FRANCIS LAURA | SIBN | Chief Executive Officer | May 7 '25 | Sell | $17.18 | 38,504 | $661,367.81 | 500,698 | |
| DUNN JEFFREY W | SIBN | Director | May 1 '25 | Sell | $13.78 | 336 | $4,628.40 | 17,354 | |
| RECUPERO ANTHONY J | SIBN | President, Commercial Ops | Apr 2 '25 | Sell | $14.15 | 3,311 | $46,852.55 | 282,370 |
Latest SI-BONE Inc. News
SIBN Breaking Stock News: Dive into SIBN Ticker-Specific Updates for Smart Investing
GlobeNewswire
17 days ago
SI-BONE to Present at Truist Securities MedTech Conference on June 17, 2025
GlobeNewswire
24 days ago
SI-BONE to Present at Goldman Sachs 46th Global Healthcare Conference on June 10, 2025
Zacks
a month ago
Wall Street Analysts See a 34.22% Upside in Si-Bone (SIBN): Can the Stock Really Move This High?
Zacks
a month ago
What Makes Si-Bone (SIBN) a Strong Momentum Stock: Buy Now?
Simply Wall St.
a month ago
Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Zacks
a month ago
Wall Street Analysts Think Si-Bone (SIBN) Could Surge 41.21%: Read This Before Placing a Bet
Simply Wall St.
a month ago
SI-BONE First Quarter 2025 Earnings: Beats Expectations
GlobeNewswire
a month ago
SI-BONE To Present at BofA Securities 2025 Healthcare Conference on May 13, 2025
Compare SIBN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SIBN SI-BONE Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.